Teva Fails To Overturn €60m EU Fine Over Provigil ‘Pay For Delay’
Firm Had Contested 2020 Decision Stemming From Investigation That Began In 2011
Teva has failed in its attempt to overturn European fines totaling €60.5m in relation to a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil).
You may also be interested in...
A report from the European Commission highlights how the enforcement of pharmaceutical antitrust rules between 2018 and 2022 increased the availability of fairly priced innovative medicines in the bloc.
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
Samsung Bioepis has received an EMA nod for its Sandoz-partnered Stelara biosimilar under the name Pyzchiva. Meanwhile, the agency’s CHMP also recommended granting centralized marketing authorizations for two Accord generics.